NCT07257198

Brief Summary

In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,570

participants targeted

Target at P75+ for phase_3

Timeline
57mo left

Started Mar 2026

Longer than P75 for phase_3

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress4%
Mar 2026Jan 2031

First Submitted

Initial submission to the registry

November 20, 2025

Completed
12 days until next milestone

First Posted

Study publicly available on registry

December 2, 2025

Completed
3 months until next milestone

Study Start

First participant enrolled

March 3, 2026

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2030

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2031

Last Updated

March 10, 2026

Status Verified

March 1, 2026

Enrollment Period

3.8 years

First QC Date

November 20, 2025

Last Update Submit

March 8, 2026

Conditions

NSTEMI - Non-ST Segment Elevation MISTEMI (ST Elevation MI)Myocardial Infarction

Keywords

Dual antiplatelet therapyNSTEMImedical treatmentSTEMIaspirinticagrelorbleedingischemic eventsrandomized trialpragmatic trialrandomized controlled trial

Outcome Measures

Primary Outcomes (2)

  • Bleeding

    Time to first BARC type 2, 3, or 5 bleeding

    From randomization to 12 months

  • Patient-oriented ischemic clinical endpoint

    Time to first composite of all-cause mortality, MI, stroke, or any coronary revascularization

    From randomization to 12 months

Study Arms (2)

Ticagrelor monotherapy

EXPERIMENTAL

Ticagrelor 90 mg orally twice daily + placebo orally once daily

Drug: Ticagrelor + placebo

DAPT with ticagrelor and aspirin

ACTIVE COMPARATOR

Ticagrelor 90 mg orally twice daily + aspirin 80 mg orally once daily

Drug: Ticagrelor + aspirin

Interventions

Ticagrelor + aspirinDRUG

Ticagrelor 90 mg twice daily + aspirin 80 mg once daily

DAPT with ticagrelor and aspirin
Ticagrelor + placeboDRUG

Ticagrelor 90 mg twice daily + placebo once daily

Ticagrelor monotherapy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥18 years;
  • Hospitalized for type 1 MI, according to the 4th Universal Definition of MI;
  • Coronary angiogram performed;
  • Planned for medical management alone, without revascularization;
  • Willingness to participate and to attend study visits;
  • Expected life expectancy ≥12 months.

You may not qualify if:

  • Patients hospitalized for type 2-5 MI, or unstable angina, according to the 4th Universal Definition of MI;
  • Patients hospitalized for a STEMI with an acute thrombotic lesion of a major epicardial vessel;
  • Elevations in cardiac biomarkers (troponins or CK-MB) that is believed by the investigator not to be of ischemic origin (e.g. myocardial injury, myocarditis, Takotsubo syndrome, etc.);
  • Confirmed or suspected spontaneous coronary artery dissection;
  • Concomitant indication for chronic oral anticoagulant;
  • Concomitant non-coronary indication for dual antiplatelet therapy;
  • Use of any non-trial antiplatelet drug that needs to be continued based on the judgement of the treating physician;
  • Previous hospitalization for MI, PCI, or CABG within 12 months;
  • Known hypersensitivity, intolerance, or contra-indication to ASA or ticagrelor;
  • Unsuitability for either randomization treatment, based on the judgement of the treating physician

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Montreal Heart Institute

Montreal, Quebec, H1Y2P3, Canada

RECRUITING

MeSH Terms

Conditions

Non-ST Elevated Myocardial InfarctionST Elevation Myocardial InfarctionMyocardial InfarctionHemorrhage

Interventions

TicagrelorAspirin

Condition Hierarchy (Ancestors)

Myocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Intervention Hierarchy (Ancestors)

AdenosinePurine NucleosidesPurinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsNucleosidesNucleic Acids, Nucleotides, and NucleosidesRibonucleosidesSalicylatesHydroxybenzoatesPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic Chemicals

Central Study Contacts

Guillaume Marquis-Gravel, MD

CONTACT

1-514-376-3330guillaume.marquis.gravel@umontreal.ca

Roseline Therrien

CONTACT

1-514-461-1300roseline.therrien@seriant.org

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate professor of clinic

Study Record Dates

First Submitted

November 20, 2025

First Posted

December 2, 2025

Study Start

March 3, 2026

Primary Completion (Estimated)

January 1, 2030

Study Completion (Estimated)

January 1, 2031

Last Updated

March 10, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations

CA(1)